ImClone Cries Fraud Over Erbitux Deal

Law360, New York (May 7, 2008, 12:00 AM EDT) -- After burying the hatchet with Repligen Corp. months ago, ImClone Systems Inc. has sued Abbott Laboratories for allegedly withholding documents that the company claims played a huge part in its decision to enter into the $65 million patent settlement over cancer drug Erbitux.

ImClone filed suit Friday in the U.S. District Court for the District of Massachusetts, claiming that Abbott deliberately concealed information on agreements that both it and Repligen made with the National Cancer Institute that could have buttressed the company's defense.

“As a result...
To view the full article, register now.